IPCXR vs PFE · rev $100.0M vs P/E 20, rev $15.03B
Inflection Point Acquisition Corp. III Rights (IPCXR) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Inflection Point Acquisition Corp. III Rights (IPCXR) common stock listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported IPCXR revenue for 2025-09-30 was $100.0M. Net income was -$90.8K. IPCXR currently screens at market cap $0.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
IPCXR currently screens at market cap $0. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the IPCXR and PFE stock pages for the full models.
Not investment advice.